Four Decades of Industry Heritage • Founded in 2007

Pioneering Quality & Excellence in Active Pharmaceutical Ingredients

Chieron Active Ingredients Pvt. Ltd. is promoted by a prominent business house in India with extensive pharmaceutical experience spanning over four decades.

20+
High-Quality APIs
Cardiovascular, CNS & Antidiabetic
350+ KL
Manufacturing Capacity
Scalable with +200 KL expansion
50+
Countries Global Reach
USA, Europe, Japan, Korea & Global
20+
Years Industry Expertise
4+ Decades Parent Legacy
Corporate Profile

Who We Are & Our Global Footprint

Chieron has established a strong, recognized presence in specific critical therapeutic segments including Cardiovascular and Central Nervous System (CNS). The company continuously adds high-value molecules and expands its global footprint across North America, Europe, Japan, Korea, Brazil, and China.

Chieron stands as a pioneer manufacturer of unique niche Active Pharmaceutical Ingredients (APIs), holding prestigious approvals including six Certificates of Suitability (COS) from EDQM, USFDA approval, and Korean FDA (KFDA) approvals. We are actively pursuing filings with ANVISA (Brazil) and cFDA (China) for our key commercial products.

Our strategic focus on Backward Integration not only ensures cost competitiveness but also guarantees supply reliability and impeccable quality control across Key Starting Materials (KSMs) to finished APIs.

Our Core Mission (Since 2007)

“Delivering Best Quality and Cost Leadership in the supply of Intermediates & APIs to customers globally while achieving the highest levels of customer satisfaction.”

Leadership Vision
At Chieron, sustainability drives innovation. Our goal is to build a business that is responsible, resilient, and ready for the future.
Chandra Kumar Verma
Managing Director & CEO
Global Accreditations

Approved Manufacturing Sites & International Certifications

Our quality systems and regulatory filings are structured to satisfy the world's most stringent regulatory authorities.

Approved

USFDA

(United States)

USFDA Approved

Approved Manufacturing Site for Active Pharmaceutical Ingredients

Approved

EDQM

(Europe)

6 COS Approvals

Approved Sites & 6 Certificates of Suitability (COS)

Accredited

PMDA

(Japan)

PMDA Accredited

Accredited Foreign Manufacturer for Pharmaceutical Ingredients

Approved

KFDA

(South Korea)

KFDA Approved

Korean FDA Approved Manufacturing & Quality Systems

In Pursuit

ANVISA

(Brazil)

ANVISA Active Filing

Approvals actively under pursuit for key commercial molecules

In Pursuit

cFDA

(China)

cFDA Active Filing

Filing and approvals actively progressing for global supply

Regulatory Agency & Scope Breakdown

Audit-Ready Facilities
Agency / AuthorityRegion / CountryCurrent StatusScope & Accreditations
USFDAUnited StatesApprovedApproved Manufacturing Site for Active Pharmaceutical Ingredients
EDQMEuropeApprovedApproved Sites & 6 Certificates of Suitability (COS)
PMDAJapanAccreditedAccredited Foreign Manufacturer for Pharmaceutical Ingredients
KFDASouth KoreaApprovedKorean FDA Approved Manufacturing & Quality Systems
ANVISABrazilIn PursuitApprovals actively under pursuit for key commercial molecules
cFDAChinaIn PursuitFiling and approvals actively progressing for global supply

Why Global Pharma Leaders Choose Chieron

Combining world-class R&D, backward integration, and certified high-capacity manufacturing.

01

Backward Integration

In-house production of key starting materials (KSMs) and advanced intermediates guarantees supply stability and protects against global raw material shocks.

02

Continuous Production

15 to 20 commercial APIs are maintained in continuous production, offering reliable 8 to 10 weeks maximum lead time for customer inventory optimization.

03

Dedicated Client Teams

Cross-functional teams led by R&D heads for innovators, and dedicated commercial execution teams for generic and specialty chemical partners.

04

Regulatory Trail Strength

Complete technical support for filing DMFs (US-DMF, CEP, Canada, Australia) with comprehensive genotoxic and nitrosamine impurity profiling.